Alzheimer’s Disease Pipeline to Witness Large R&D Investment in the Coming Years

Alzheimer’s Disease Pipeline Analysis

According to a new research report Alzheimer’s Disease Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Alzheimer’s disease currently exhibits a pipeline with 89 active drug candidates.

Alzheimer’s disease pipeline offers novel therapeutic targets for the treatment of Alzheimer’s disease.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample

The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=alzheimers-disease-pipeline-analysis

Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.

 

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

%d bloggers like this: